A Phase 1 Study of Kappa and Mu Opioid Receptor Occupancy Associated With Repeated Dosing of LY24516302
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Aticaprant (Primary)
- Indications Anxiety disorders
- Focus Therapeutic Use
- Acronyms FASTMAS
- 26 May 2015 Planned End Date changed from 1 May 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
- 26 May 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 25 Aug 2014 New trial record